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Hepatitis C in dialysis patients: Relationship to blood transfusions,
dialysis and liver disease. Antibodies to hepatitis C virus (anti-HCV)
were determined in an unselected group of 340 patients with chronic
renal failure treated with maintenance dialysis. A second generation
hepatitis C virus (HCV) enzyme-linked immunosorbent assay (ELISA)
was used and confirmation made by a second generation recombinant
immunoblot assay (RIBA). Sixteen patients (4.7%) were anti-HCV
positive and 8 (2.4%) were anti-HCV indeterminate. All anti-HCV
positive and anti-HCV indeterminate patients had received blood
transfusions. No statistically significant differences were found between
anti-HCV positive and indeterminate patients considering blood trans-
fusions, dialysis and liver disease. The combined group of anti-HCV
positive and indeterminate patients had had more blood transfusions (P
< 0.005) and had been on dialysis for a longer period (P < 0.01)
compared with anti-HCV negative patients. Further, significant corre-
lation with elevation of transaminases and anti-HCV was observed (P <
0.001). Thirty patients (8.8%) had elevated transaminase levels and 13
(43%) of these were anti-HCV positive or indeterminate. In conclusion,
HCV infection accounts for a substantial proportion of liver disease in
dialysis patients, probably most often transmitted by blood transfusions
but other routes of transmission could not be excluded.
Elevations of transaminase levels are frequently observed in
patients with chronic renal failure on long-term dialysis [1—31. In
addition, chronic non-A, non-B hepatitis (NANBH) is a major
cause of liver disease in renal transplant recipients, and chronic
liver disease contributes substantially to morbidity among long-
term survivors of renal transplantation [4, 5]. The etiology of
liver disease in patients with chronic renal failure is not always
known. However, NANBH is one of the prime causes of both
acute and chronic liver disease in this population [1—3]. The
development of a diagnostic test for hepatitis C virus antibodies
(anti-HCV) has documented hepatitis C virus (HCV) to be the
major cause of both acute and chronic NANBH [6—8]. Using
first generation techniques the prevalence of anti-HCV among
patients on long-term dialysis has been found to vary from 2 to
47% [8—15]. However, this large variation in anti-HCV preva-
lence may be explained by selection bias and by the rather low
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sensitivity and specificity of the first generation tests. The route
of hepatitis transmission in this population is not fully eluci-
dated as there have been contradictory reports about the
correlation with blood transfusions and hemodialysis raising the
question of nosocomial transmission of HCV [9, 10, 12, 15—17].
We have used a highly sensitive, second generation enzyme-
linked immunosorbent assay (ELISA), and confirmation by a
second generation recombinant immunoblot assay (RIBA) to
determine the prevalence of anti-HCV in a group of unselected
patients with chronic renal failure who were on long-term
dialysis treatment, and examined the relationship to blood
transfusions, duration of dialysis and to liver disease as re-
Ilected by transaminase elevations.
Methods
Study
This study comprises a total of 340 patients with chronic renal
failure who were treated with long-term dialysis in three Uni-
versity Hospitals in Copenhagen, representing 99% of all pa-
tients treated with maintenance dialysis in this area. The
association between anti-HCV seropositivity and the following
basic variables were studied: the duration and mode of dialysis,
number of renal transplantations, number of blood transfusions
received, aminotransferase levels, whether or not the patient
was born or raised outside Western Europe, and hepatitis B
status. The investigation was approved by the regional ethical
committee and informed consent was obtained from each
patient. Four patients (1%) declined participation.
Patients
The median age of the patients was 54 years (range 7 to 83),
and 131(39%) of the 340 patients were females. The etiology of
renal failure was: chronic glomerulonephritis (23%), polycystic
kidney disease (15%), hypertension and nephrosclerosis (12%),
diabetic nephropathy (8%), pyelonephritis (7%), end-stage renal
disease of unknown etiology (20%) and others (15%). The
patients had been on dialysis for median 25 months (range 1 to
230). One hundred fifty patients had only been on hemodialysis
(median duration 30 months, range 1 to 230). One hundred ten
patients had only been on continuous ambulatory peritoneal
dialysis (median duration 15 months, range 1 to 120). Twenty-
nine of the patients (8.5%) were born or raised outside Western
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Europe. One patient had a history of intravenous drug abuse.
Two patients were hepatitis B surface-antigen positive and none
had antibodies to the human immunodeficiency virus.
Dialysis
Artificial kidneys were not reused and dialysis was performed
with disposable kits, syringes, and needles. Disinfection of the
dialysis machines included heating between dialyses by circu-
lation of hot water (80°C) for 25 minutes. Chemical disinfection
was not routinely used. Ordinary maintenance was according to
directions given by the manufacturer (Gambro, Sweden). No
special precautions were taken concerning patients with sus-
pected NANB hepatitis or patients with unexplained elevated
transaminases.
Laboratory tests
Data and blood samples were obtained from October 1990 to
March 1991. Serum was immediately frozen to minus 30°C and
stored for later analysis.
All samples were tested for HCV antibodies using a second
generation ELISA from Ortho Diagnostic Systems (Raritan,
New Jersey, USA). Samples which were nonreactive in the
initial ELISA test were considered ELISA negative and were
not tested further. Initially reactive samples were re-tested by
ELISA in duplicate. Samples which were reactive in one or
both re-tests were considered ELISA positive.
ELISA positive samples were further tested by a second
generation RIBA from Chiron (Emeryville, USA) in order to
confirm the presence of anti-HCV. The second generation
RIBA HCV test included four separate HCV antigen bands
which together covered the same expression of viral antigens
present in the HCV ELISA test. The RIBA HCV antigen bands
were derived from three different regions of the HCV genome,
the 5-1-1 and the clOO-3 antigens from the non-structural NS4
region, the c33c antigen from the non-structural NS3 region,
and the c22-3 antigen from the structural core region. All the
HCV antigens were fused to superoxide dismutase (SOD) as
part of the recombinant DNA technology. Hence, the RIBA
HCV test included an additional band with SOD-antigen in
order to exclude reactivity due to the presence of SOD anti-
bodies. Interpretation of the RIBA HCV test results was carried
out according to the directions outlined by the manufacturer. In
brief, the intensity of the reaction for each antigen band was
scored on a scale from 0 to 4+. Only bands with an intensity of
1 + or more were considered reactive. Sera reacting with two,
three or four viral antigen bands were designated as RIBA
positive, sera reacting with only one viral antigen band as RIBA
indeterminate, and sera without reactive viral antigen bands as
RIBA negative.
Based on the ELISA and RIBA results, the patients could be
stratified into three categories: (a) ELISA positive, RIBA
positive patients in whom anti-HCV definitely were present; (b)
ELISA positive, RIBA indeterminate patients in whom anti-
HCV probably were present; and (c) ELISA negative patients
together with ELISA positive, RIBA negative patients in whom
anti-HCV could not be detected. In the following, patients from
groups a, b and c were designated as anti-HCV positive,
anti-HCV indeterminate and anti-HCV negative patients, re-
spectively.
Transaminases (aspartate aminotransferase or alanine amin-
otransferase) were measured routinely every month or every
third month at the three dialysis centers. The aminotransferases
were analyzed with standard automated analyzer techniques.
The values were considered elevated when above 40 U/liter,
which is the upper reference value at our laboratories.
Statistics
Non-parametric statistical analyses were used, that is, two-
way tables were performed using the chi square test or Fisher's
exact test, and continuous variables were analyzed using the
Mann-Whitney rank sum test. Statistical probability of less than
0.05 was considered significant.
Results
Among the 340 dialysis patients tested with second genera-
tion HCV ELISA we found 28 (8.2%) ELISA positive patients.
Supplemental testing with second generation HCV RIBA
showed that 16 of the 28 ELISA positive patients were MBA
positive, eight were RIBA indeterminate and four were RIBA
negative. Thus, 16 patients (4.7%; 95% confidence limits 2.7 to
7.5%) were classified as anti-HCV positive, eight (2.4%) pa-
tients as anti-HCV indeterminate and 316 (92.9%) as anti-HCV
negative. There was no statistically significant difference be-
tween the dialysis centers concerning the prevalence of anti-
HCV. Results of the antigen bands of the anti-HCV positive and
indeterminate patients are seen in Table 1. Fifteen of the 16
anti-HCV positive patients were reactive in the c33c band and
all were reactive in either c33c or c22-3. Six of the eight
anti-HCV indeterminate patients were reactive in the c22-3
band and one was reactive in c33c.
The presence of anti-HCV and correlation with basic vari-
ables are seen in Table 2. There were no statistically significant
differences between anti-HCV positive, indeterminate and neg-
ative patients concerning sex, age, number of renal transplan-
tations, or whether or not the patient was born or raised outside
Western Europe. There was a statistically significant difference
in number of blood transfusions between anti-HCV positive and
indeterminate patients compared with anti-HCV negative pa-
tients (30 vs. 13 transfusions, P <0.005). All anti-HCV positive
and indeterminate patients had received blood transfusions.
Anti-HCV positive and indeterminate patients had been on
dialysis for a longer period than the anti-HCV negative patients
(44 vs. 25 months, P < 0.01). Two of the anti-HCV positive
patients had been solely on continuous ambulatory peritoneal
dialysis. Not surprisingly, there was a highly significant corre-
lation (P < 0.001) between the duration of dialysis and the number
of blood transfusions (data not shown). None of the two hepatitis
B surface-antigen positive patients were anti-HCV positive.
Correlation with elevations of transaminases is seen in Table
3. In one-third of the patients the elevation of transaminases
could be related to HCV infection. At the time of testing, 30
patients (8.8%) had elevated transaminase levels, and 13 (43%)
of these were anti-HCV positive or indeterminate. Thirty-five
patients had had elevations of transaminases for more than six
months and 10 of these were anti-HCV positive, representing
63% of the anti-HCV positive patients. Two of the anti-HCV
positive patients had always had normal transaminases until
one month before testing, but elevated transaminases after-
wards (patient no. 2 and no. 5). Only one anti-HCV positive
indeterminate patient
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Table 1. Profile of antigen bands in second generation recombinant
immunoblot assay (RIBA) in 16 anti-HCV and 8 anti-HCV
Numbers account for band intensity.  I+ represents a reactive band(shaded). Patients with 2 reactive bands are interpreted as RIBA
positive and patients with only one band as RIBA indeterminate.
Table 2. Hepatitis C virus antibodies and basic variables in 340
dialysis patients
P value
Duration of dialysis 38 (9—167) 66(11—160) 25 (1—230) < o.ola
months
Number of blood 30 (4—188) 27 (12—176) 13 (0—327) < 0.005
transfusions
Age years 55 (12—66) 54 (7—69) 54 (9—83) NS
Female/male 6/10 3/5 122/194 NSb
Born/raised outside 3 (19%) 1 (13%) 25 (7.9%) NSb
Western Europe
Renal 5 (31%) 2 (25%) 85 (27%) NSb
transplantation
patient had always had normal transaminase levels. Two pa-
tients (no. 1 and no. 6) had symptoms and signs indicating
NANBH, which in both cases was verified by liver biopsy.
Patient number 1 developed clinical and biochemical evidence
of severe liver disease three months after transfusion of blood,
which was found to be anti-HCV negative by routine screening
using first generation ELISA. Liver biopsy verified chronic
viral hepatitis seven months after blood transfusion.
Table 3. Hepatitis C virus antibodies and transaminase levels in 340
dialysis patients
Anti-HCV Anti-HCV Anti-HCV
positive indeterminate negative P(N = 16) (N = 8) (N = 316) values
Elevation at present 11(69%) 2 (25%) 17 (5.4%) < 0.001
Elevation within the 13 (81%) 2 (25%) 24 (7.6%) < 0.001
last 3 months
Elevation  180 10 (63%) 1 (13%) 24 (7.6%) < 0.001
days
Always normal 1 (6%) 2 (25%) 231 (73%) < 0.001
a Fisher's exact test, anti-HCV positive and indeterminate patients
vs. anti-HCV negative patients
Considering the use of the highly sensitive, second generation
ELISA test, the prevalence of anti-HCV among Danish patients
on long-term dialysis seems low compared to other dialysis
centers in western countries [8, 9, 11, 13, 17—191. We found a
prevalence of 8.2% anti-HCV ELISA positive and only 4.7%
anti-HCV RIBA positive patients. This is still considerably
higher than among blood donors in Denmark where the preva-
lence has been determined to be 0.3% using the first generation
ELISA test [201. Due to the low specificity of the first genera-
tion ELISA test, most of them probably are false positive
reactions, Fifteen of 16 anti-HCV positive patients were reac-
tive in the c33c band and all were reactive in either c33c or
c22-3, representing a non-structural and a core-associated anti-
gen, respectively, characteristic of the second generation anti-
HCV test. Interestingly, seven of the 16 anti-HCV positive
patients did not react with either clOO-3 or 5-1-1 and therefore
probably would have been overlooked by the first generation
HCV ELISA. Even more strikingly, seven of eight anti-HCV
indeterminate patients were reactive in either c22-3 or c33c, and
thus might have been missed by the first generation test as well.
Comparing anti-HCV positive and indeterminate patients we
found no statistically significant differences concerning number
of blood transfusions, duration of dialysis or transaminase
activity. In our opinion this fact and the similarity of the antigen
band profile between anti-HCV positive and indeterminate
patients justifies the pooling of the two groups for the statistical
analyses. The number of anti-HCV indeterminates may reflect
the relative immunodeficiency of the uremic patients who might
be unable to mount or sustain significant antibody titers [21].
Investigation of HCV-RNA by polymerase chain reaction
would clarify this presumption.
Anti-HCV seropositivity correlates with both number of
blood transfusions and duration of dialysis. There was a highly
significant correlation between these variables themselves.
However, in our material we are not able to statistically
estimate the relative importance of each variable. However, all
of the anti-HCV positive and indeterminate patients did receive
blood transfusions. The total number of blood transfusions,
given was 11,506. On the assumption that all cases of anti-HCV
among the dialysis patients were transfusion transmitted, we
would estimate the prevalence of HCV infection among blood
donors to be approximately 0.2%. This prevalence is somewhat
Aminotransferase
levels
Discussion
Anti-HCV Anti-HCV
positive indeterminate(N=16) (N=8)
Anti-HCV
negative(N = 316)
All continuous variables are median (range).
a Mann-Whitney rank sum test; anti-HCV positive and indeterminate
patients vs. anti-HCV negative patientsb Chi square test
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higher than the prevalence found by second generation anti-
HCV screening in Danish blood banks, implicating that other
routes of transmission may be present.
The mode of transmission of HCV among patients on dialysis
has not yet been fully elucidated, Correlation with duration of
hemodialysis but not with blood transfusions has been de-
scribed [9, 12, 171. Interestingly the prevalence of anti-HCV
varies considerably between different dialysis centers within
the same country [9, 13]. Furthermore, anti-HCV prevalence
higher than in the general population has been described in
non-transfused hemodialysis patients [9, 10, 12, 13, 16—18], and
an outbreak of HCV infection in a dialysis center among
patients who had not received blood transfusions has been
reported [22]. This points to a role of nosocomial transmission
of HCV and raises the question of how anti-HCV positive
patients should be handled in dialysis centers [12, 17, 18].
The spectrum of liver disease in patients with chronic renal
failure and in patients following renal transplantation is varied,
and the etiology is often unknown and probably multifactorial
[4]. Biochemical evidence of hepatic disease among patients on
dialysis is not negligible [1—3, 11]. In our population the
prevalence of hepatitis B surface-antigen is low compared to
other dialysis centers. Nevertheless, elevation of transaminases
within a period of three months is seen in 12% (95% confidence
limits: 8 to 15%). Our study shows that the majority of the
anti-HCV positive patients have persistently elevated transam-
inases indicating chronic hepatitis, as noted by other investiga-
tors [11, 15, 19], and HCV may account for at least one-third of
chronic hepatic disease in patients on dialysis [11, 13]. Lower
incidence of liver affection has been described [10, 121, but use
of the more sensitive second generation tests seems to unravel
the causes of previously unexplained transaminase elevations.
Although hepatitis C infection is often subclinical or with a
mild clinical course, hepatitis C evolves into chronic infection
in about 50% of cases [5, 7]. The course of the chronic infection
is often slowly progressive with fluctuating levels of transami-
nases, but the long-term prognosis seems to be as serious as in
chronic hepatitis B virus infection, and may result in cirrhosis in
approximately 20% of patients with chronic hepatitis [5, 7].
Administration of interferon in patients with chronic hepatitis C
is effective in controlling disease activity in most patients
assessed from transaminase levels, histology and frequency of
relapse even after cessation of treatment [7]. However, no
information is available on the treatment of dialysis patients, as
renal failure is a relative contraindication to treatment with
interferon.
HCV infection among dialysis patients and among kidney
transplant recipients is a major problem as reflected by the
biochemical evidence of hepatic disease. However, the impact
of HCV infection to the long-term morbidity and mortality in
this population is not yet known.
Reprint requests to Freddy Knudsen, M.D., Department of Anaes-
thesia and Intensive Care Medicine, Herlev Hospital, University of
Copenhagen, DK-2 730 Herlev, Denmark.
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